The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Stephanie Lira discussing scaling operations in theranostics clinical research. There has been tremendous ...

Examples include (i) “low” PSMA uptake in a slightly enlarged lymph node (s) in men with newly diagnosed or recurrent ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

A short course of darolutamide (Nubeqa) enhanced the imaging signal of prostate-specific membrane antigen (PSMA)-PET in a ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Study combines highly focused radiation with targeted radioactive therapy drug designed to seek out and destroy cancer cells with minimal damage to healthy tissue The Phase 2 trial, called ANDROMEDA, ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...